Skip to main
  1. Stocks
  2. Insight Molecular Diagnostics Inc
  3. Forecast
IMDX

IMDX Stock Forecast & Price Target

IMDX Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 75%
Buy 0%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Insight Molecular is supported by a compelling mix of reimbursement tailwinds, clinical validation, and expanding commercial pathways for its dd-cfDNA platform. The July 2026 MolDx LCD doubled testing frequency to four tests per year in years 2-3, GraftAssureCore is reimbursed at $2,753 per result, and 3Q26 revenue rose 115% year over year to $559K while gross margin reached 75.1%, with cash burn improving to -$7.3M. Management also has multiple catalysts in motion, including GALACTIC enrollment, ~7 U.S. centers already planning in-house testing in 2027, and a clear path to broader adoption through FDA authorization, Europe expansion, and the heart opportunity with a >$100M U.S. TAM.

Bears say

Insight Molecular is facing a fundamentally weaker outlook because the FDA has asked for substantial additional evidence on GraftAssureDx, including an independent accuracy study and biopsy slide review, pushing expected approval to around mid-2027 and launch to Q3'27. The company’s Q2'26 performance underscores execution pressure, with revenue of just $239k, a net loss of -$11.3M, Adj. EBITDA of -$7.8M, and roughly $18.7M of cash after burning about $10M in the quarter. A recent $15M equity offering at $1.75 per share also highlights ongoing dilution risk, while regulatory, reimbursement, and adoption hurdles could delay monetization even if the product is ultimately approved.

IMDX has been analyzed by 4 analysts, with a consensus rating of Buy. 75% of analysts recommend a Strong Buy, 0% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insight Molecular Diagnostics Inc and is not a guaranteed prediction by Public.com or investment advice.

IMDX Analyst Forecast & Price Prediction

Get the latest IMDX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in IMDX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insight Molecular Diagnostics Inc (IMDX) Forecast

Analysts have given IMDX a Buy based on their latest research and market trends.

According to 4 analysts, IMDX has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insight Molecular Diagnostics Inc (IMDX)


IMDX Analyst Forecast & Price Prediction

Get the latest IMDX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in IMDX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover IMDX stock data and trends